Cyprotex takes space at Alderley Park BioHub
CYPROTEX, the Anglo-US drug testing and contract research company, is taking space at BioHub, a new bioscience centre at AstraZeneca’s Alderley Park research campus.
The AIM-listed company, which currently has operations in Macclesfield and Massachusetts, develops software used by large pharmaceutical groups to predict the effect of medication.
Cyprotex said BioHub will provide additional capacity for laboratories and office space.
It said the expansion followed “highly encouraging” growth figures for the business in the first six months of the year, with a revenue increase of 22.3% and a record half yearly operating profit of £317,000.
Chief executive Dr Anthony Baxter said: “As we continue to see significant growth in our business, it has been necessary to expand our facilities to meet the increased demand. We are therefore delighted to announce the signing of a lease for new cutting-edge facilities at BioHub in Alderley Park. The location of the facility is ideal for transport links, both by air and road, which is important as Cyprotex expands its international footprint.”
The BioHub is being run by Nottingham-based life sciences incubation business BioCity. It will initially provide 36,000 sq ft of high-end laboratory and office facilities for early-stage and growing firms engaged in innovative drug discovery and development.
Other tenants to move to the site include Blueberry Therapeutics, Imagen Biotech and Redx Anti-Infectives, a subsidiary of Liverpool-based Redx Pharma. It is hoped they will help replace the 2,000 high value jobs that are bieng lost to Cambridge as a result of AstraZeneca’s decision to relocate its research and development base.
